Cara Therapeutics Announces Completion of Interim Statistical Assessment and Small Increase in Target Enrollment for KALM-2 Phase 3 Global Trial of KORSUVAâ„¢ Injection in Hemodialysis Patients with Pruritus
Patient enrollment increased approximately 20% to maintain >90% statistical power.
Read More
